Supernus Pharmaceuticals, Inc., A Biopharmaceutical Company Focused On Developing And Commercializing Products For The Treatment Of Central Nervous System (Cns) Diseases, Today Announced That The U.S. Food And Drug Administration (Fda) Approved Qelbree (Viloxazine Extended-Release Capsules) For The Treatment Of Attention-Deficit Hyperactivity Disorder (Adhd) In Pediatric Patients 6 To 17 Years Of Age.&Ldquo;Based On The Efficacy Demonstrated In The Clinical Program, We Believe Qelbree Offers A Unique New Alternative For The Treatment Of Adhd,&Rdquo; Said Jack A. Khattar, President And Chief Executive Officer Of Supernus Pharmaceuticals. &Ldquo;Qelbree Provides Prescribing Physicians And Patients Living With Adhd A Therapy That Is Not A Controlled Substance With Proven Efficacy And A Tolerable Safety Profile. We Are Grateful To The Patients, Families And Their Care Givers Who Participated In And Supported Our Research.&Rdquo;&Ldquo;Adhd Is One Of The Most Common Mental Health Issues In The U.S.,&Rdquo; Said Andrew J. Cutler, M.D., Clinical Associate Professor Of Psychiatry At Suny Upstate Medical University, And Chief Medical Officer, Neuroscience Education Institute. &Ldquo;The Right Treatment Is Key For Children And Adolescents, As They Grow And Navigate School And Social Relationships. This Approval Offers A Novel Once A Day Sprinkleable Non-Stimulant That Can Be A Great Option For Children And Adolescents With Adhd.&Rdquo;The Approval Of Qelbree Is Supported By Data From An Extensive Development Program Consisting Of Four Phase Iii Clinical Trials That Studied More Than 1000 Pediatric Patients From The Age Of 6 To 17 Years. In December 2020, The Company Announced Positive Results From A Phase Iii Trial In Adult Patients With Adhd And Plans To Submit A Supplemental New Drug Application To The Fda For Qelbree In Adults In The Second Half Of 2021.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!